Found 25 matching trials
The Role of Fibroblast Activation in Uterine Fibroid
N/AUterine fibroids (UFs), also called uterine leiomyomas or myomas, are stero...
Location
Assiut university -Faculty of medicine- Departement of Biochemistry
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
PHASE1The overall rationale of this study evaluating tolerance and efficacy of LY...
Location
Centre Geroges François Leclerd
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
PHASE2The purpose of this study is to evaluate the antitumor efficacy and the saf...
Location
Institut Bergonié
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
PHASE1Afuresertib, an AKT inhibitor, has shown in vitro and in vivo activity in m...
Location
Novartis Investigative Site
A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
PHASE2A multicentre prospective, randomised, phase II interventional study in mCR...
Location
Royal Marsden Hospital
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer
PHASE1This study will examine tissue specimens from patients participating in a t...
Location
British Columbia Cancer Agency (BCCA)
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
PHASE2This is a single arm, open-label, Phase Ib/II study to evaluate the safety,...
Location
GSK Investigational Site
Prostate Cancer Biomarker Enrichment and Treatment Selection
PHASE2The purpose of the pre-study screening is to test for DNA abnormalities or ...
Status
Active Not Recruiting
Location
Cross Cancer Institute
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
PHASE1The purpose of this study is to test the safety and safest highest dose of ...
Location
University of California, San Francisco
Muscadine Plus (MPX) In Men With Prostate Cancer
PHASE3This research is being done to determine if men with rising PSA after initi...